Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

NCT03646461 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Ibrutinib 560mg PO daily (Imbruvica)
DRUG: Cetuximab
DRUG: Nivolumab

Sponsor

University of California, San Diego

Collaborators

[object Object]